Physician profile
Helen Rostamloo
NPI 1285759514
$2,365.88
in general payments reported to CMS, 2019-2025
19 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2021: $205 · 2022: $610 · 2023: $647 · 2024: $337 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,109.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $846.18 | 2021-2025 | Linzess, Viberzi, Ubrelvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $384.86 | 2019-2023 | Xifaxan |
| Glaxosmithkline, LLC. | $151.34 | 2022-2024 | Trelegy Ellipta |
| Abiomed | $138.49 | 2019 | |
| Amgen INC. | $138.38 | 2022-2023 | Otezla, Repatha, Prolia |
| Lilly USA, LLC | $124.77 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $123.01 | 2019 | |
| Pfizer INC. | $115.84 | 2022-2024 | |
| Vivus LLC | $83.92 | 2022-2024 | Pancreaze |
| Novo Nordisk INC | $46.75 | 2023-2024 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $44.07 | 2021 | |
| Radius Health, INC. | $33.92 | 2025 | Tymlos |
| Kowa Pharmaceuticals America, INC. | $25.36 | 2024 | Zoryve |
| Galderma Laboratories, L.P. | $23.64 | 2021 | |
| Idorsia Pharmaceuticals US INC | $22.05 | 2023 | Quviviq |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $20.83 | 2021 | |
| Currax Pharmaceuticals LLC | $17.91 | 2023 | Contrave |
| Genentech USA, INC. | $13.32 | 2022 | |
| Hologic Sales and Service, LLC | $11.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helen Rostamloo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.